The Harvard geneticist says we already know enough biology to start building longevity medicine. The first human data, a ...

Pfizer chief oncology officer Jeff Legos talked to Scrip about the Phase III failure of sigvotatug vedotin in previously ...

Biotech/Merck’s sacituzumab tirumotecan is set to supersede chemotherapy in combination with Keytruda in first-line, ...

FDA retired Chief Information Officer title, but Sanjay Sahoo moved to temporarily lead new Office of Mission Information ...

Australia’s regulator weighs in on debate about whether intention or function should decide regulatory status for AI products ...

Another positive study for AstraZeneca’s PD-L1 blocker Imfinzi could send it into a third bladder cancer population, while ...

The Swiss company's candidate has comfortably surpassed Lumakras and Krazati; significant survival data and an impressive ...

The Madrid meeting rose to acclaim data “of a magnitude not previously seen” for a combo set to become first-line maintenance ...

CMR Surgical CEO Massimiliano Colella said Stryker’s $400m investment is structured so CMR keeps training, marketing and ...

P&G plans to help Thorne scale its business with supply chain, ingredient qualification and marketing capabilities while ...

The FDA's drugs and biologics center directors said lessons from the rare disease “mindset shift” could be leveraged for ...

Tango’s PRMT5 inhibitor combined with Revolution Medicines’ Rasonque shows durability of effect in updated data from a Phase ...